Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 12, 2022
BD First Participant in Intermountain’s ‘Impact Hire’ Program for Strategic Suppliers SALT LAKE CITY (May 12, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global...
-
May 12, 2022
510(k) Clearance of BD COR™ MX Instrument Elevates Standard of Care for Sexually Transmitted Infections FRANKLIN LAKES, N.J., May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company)...
-
May 11, 2022
Expanded Collaboration Agreement to Make Less Invasive Blood Sample Collection More Convenient and Patient Centered AUSTIN, Texas and FRANKLIN LAKES, N.J., May 11, 2022 /PRNewswire/ -- Babson...
-
May 5, 2022
Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline...
-
May 2, 2022
Scientific Advisory Board Will Review Company Innovation Pipeline and Advise on Emerging Trends in Health Care, Science and Technology FRANKLIN LAKES, N.J., May 2, 2022 /PRNewswire/ -- BD (Becton,...
-
Apr 29, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the BofA Securities 2022 Healthcare Conference on Wednesday,...
-
Apr 26, 2022
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.87 per common share, payable on June 30, 2022 to holders of record on June 9, 2022....
-
Apr 26, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been recognized by Forbes as one of the top employers in the U.S. for...
-
Apr 25, 2022
Developed with novel dye technology and AI guidance, new BD Horizon RealYellow™ 586 Reagents have potential to accelerate discovery and drug development in oncology, autoimmune disorders and...
-
Apr 22, 2022
Institute will drive sustainable innovation in three areas of environmental stewardship, furthering progress toward the company's 2030+ environmental, social and governance (ESG) commitments...
-
Apr 7, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report financial results for its second quarter of fiscal year 2022 on Thursday, May 5, 2022. A news release will be...
-
Apr 1, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has completed its spinoff of Embecta Corp. (embecta) (NASDAQ: EMBC), which...
-
Mar 31, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Alberto Mas has informed the company of his intent to retire from BD, effective at...
-
Mar 30, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced the early results and pricing terms of Morgan Stanley & Co. LLC's ("Morgan Stanley")...
-
Mar 30, 2022BD Rhapsody™ TCR/BCR Multiomic Assay speeds discovery in autoimmune disorders, immuno-oncology and infectious diseases
FRANKLIN LAKES, N.J. (Mar 30, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, recently released the BD Rhapsody™ TCR/BCR Multiomic Assay,...
-
Mar 25, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been named to Newsweek's inaugural list of "America's Most Trusted...
-
Mar 21, 2022
Record date for spin-off is March 22, 2022 "When Issued" trading of embecta common stock is expected to begin on March 21, 2022, under the ticker "EMBCV" BD expects the spin-off of embecta to be...
-
Mar 16, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced that Morgan Stanley & Co. LLC ("Morgan Stanley") has commenced cash tender offers (each,...
-
Mar 1, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of William "Bill" Brown to its board of directors, effective Feb. 28, 2022.
-
Feb 25, 2022
FRANKLIN LAKES, N.J. and INDIANAPOLIS (Feb. 25, 2022) – USA Track & Field and BD, a leading global medical technology company, today announced the extension of BD’s sponsorship through 2022....
-
Feb 24, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will virtually present at the Cowen 42nd Annual Health Care Conference via...
-
Feb 23, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Shana Neal has been appointed chief people officer, effective April 4, 2022. Neal,...
-
Feb 23, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that embecta, the diabetes care business that is expected to spin off from BD on April 1,...
-
Feb 22, 2022Company is No. 1 Best Large Employer in Health Care Equipment & Services Industry
FRANKLIN LAKES, N.J., Feb. 22, 2022 -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that it ranked No. 1 in the Health Care Equipment &...
-
Feb 8, 2022Organizations including Superhuman Use BD Veritor™ At-Home COVID-19 Test with the ReturnSafe Platform to Keep Employees Safe at Work
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with ReturnSafe, the all-in-one software solution for COVID-19 employee...